Could a simple pump flow measure predict organ health in heart device patients?
NCT ID NCT07633535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with end-stage heart failure who have a mechanical heart pump (LVAD). It checks whether the pump's flow rate, adjusted for body size, is linked to liver and kidney function and the chance of being readmitted to the hospital. The goal is to see if this measure could help doctors monitor patients better.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If a link is found, doctors might use the LVAD index to better predict organ function and readmission risk in heart failure patients with these devices.
- What could go wrong
- This is a small, observational study with only 34 participants, so results may not apply broadly. It looks for associations, not cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akdeniz University Faculty of Medicine
Antalya, 07070, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gentler tug on the Heart's reins spark recovery?
- Heart pump vs. pills: which keeps End-Stage heart failure patients alive longer?
- Could a common diabetes drug boost heart pump recovery?
- Can a heart Pump's data predict who will recover?
- Heart pump patients to test Smartwatch-Guided home workouts
- New study aims to simplify heart monitoring for pump patients